The Influence of Concomitant Irritable Bowel Syndrome on Gastro-Oesophageal Reflux Disease Symptoms and Severity.

Launched by THE LEEDS TEACHING HOSPITALS NHS TRUST · Sep 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the connection between irritable bowel syndrome (IBS) and acid reflux, also known as gastro-oesophageal reflux disease (GERD). The researchers want to find out if people with IBS experience different or more severe acid reflux symptoms compared to those without IBS. Participants will complete two questionnaires to help categorize their symptoms and will undergo tests to measure how well their esophagus (the tube that carries food to the stomach) functions and how much acid reflux occurs over a day. By analyzing this information, the study aims to better understand the relationship between IBS and acid reflux, which could lead to improved treatments for both conditions.

To be eligible for this trial, participants must be referred for specific tests at Leeds Teaching Hospitals and be between the ages of 18 and 75. They should also be able to understand and agree to participate in the study. Participants can expect to answer questions about their symptoms and undergo tests that measure the function of their esophagus and the amount of acid reflux they experience. This trial is not yet recruiting, but if you're interested, it's important to be aware of the preparation needed before testing, such as fasting and avoiding certain medications.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients that have been referred for high-resolution oesophageal manometry and ambulatory pH or multichannel intraluminal impedance-pH (MII-pH) studies at the Gastrointestinal Physiology department at Leeds Teaching Hospitals NHS Trust from September 2024 to January 2025 (dates subject to change depending on acquisition of approvals).
• • All participants must be fully consenting with a good understanding of what the study involves.
• Exclusion Criteria:
• • Patients aged \<18 years.
• • Those that have not followed the pre-test preparation criteria, including: those that have not been sufficiently fasted prior to testing (6 hours for food, 3 hours for drinks); those that have not retained from taking proton pump inhibitor medication for 7 days prior to testing (lansoprazole, omeprazole, esomeprazole, rabeprazole, pantoprazole), histamine-2 receptor antagonist medication for 2 days prior to testing (famotidine, cimetidine, nizatidine), and other antacids on the day of testing (Gaviscon, Rennies, Peptac, etc).
• • Patients that lack the capacity to understand, retain, and communicate information to accurately complete questionnaires relating to their experienced symptoms.
• • Non-consenting patients.